# Can Neoadjuvant Chemotherapy Cause Postoperative Hydronephrosis After Radical Cystectomy?

## TL;DR

This study finds that neoadjuvant chemotherapy increases the risk of postoperative hydronephrosis and revision surgery in bladder cancer patients after radical cystectomy.

## Contribution

The study identifies neoadjuvant chemotherapy as an independent risk factor for postoperative hydronephrosis after radical cystectomy.

## Key findings

- Neoadjuvant chemotherapy is significantly associated with postoperative hydronephrosis (P = 0.048).
- NAC increases the likelihood of needing revision surgery (P = 0.002).

## Abstract

Objective: This study's objective is to assess the effect of preoperative factors on postoperative hydroureteronephrosis (HUN) after radical cystectomy (RC) in patients with bladder cancer (BC).

Methodology: Patients who underwent RC for BC between January 2019 and November 2022 and had unilateral or bilateral postoperative HUN were retrospectively analyzed. Patients without preoperative HUN but with postoperative HUN constituted the patient group, while patients without both preoperative and postoperative HUN constituted the control group, and they were compared with each other.

Results: Neoadjuvant chemotherapy (NAC) and postoperative metastasis were positively correlated with postoperative HUN (r = 0.238, P = 0.007, and r = 0.203, P = 0.021, respectively). Multivariate logistic regression analysis showed that the postoperative HUN was significantly associated with NAC (P = 0.048; Exp(B) = 6.896, 95% confidence interval [CI] 1.02-46.9) but not associated with the presence of metastasis (P = 0.054). Moreover, NAC increased the possibility of undergoing revision surgery (P = 0.002; Exp(B) = 26.9, 95% CI 3.2-225).

Conclusions: NAC is an independent factor for impaired anastomotic healing, increased postoperative HUN, and the need for revision surgery in patients with BC.